Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity
- PMID: 33012325
- DOI: 10.1016/j.iac.2020.06.003
Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity
Abstract
Biologic and other therapies used for the treatment of immune-mediated hypersensitivity conditions, and in people with immune-mediated hypersensitivity, can trigger a wide variety of immune-related adverse drug reactions and immunologically mediated drug hypersensitivities. These range from acute-onset immunoglobulin E-mediated allergies to delayed-onset T-cell-mediated hypersensitivities. Certain therapeutic and diagnostic agents can directly activate mast cells. Biologic agents used to treat immune-mediated hypersensitivity can also globally upregulate or downregulate the immune system leading to pathologic reactions, including cytokine storm and hypogammaglobulinemia.
Keywords: Adenovirus vector; Adverse drug reaction; Allergy; Complement; Cytokine storm; Gene transfer; Hypersensitivity; Hypogammaglobulinemia.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure E. Macy has received research grants to study drug allergy from ALK. He has served on data and safety monitoring boards for BioMarin and Audentes. He has performed consulting for Kalobios and Audentes. He is a member of the Ask an Expert Panel of the American Academy of Allergy, Asthma, and Immunology.
Similar articles
-
Immune reactions to drugs and diagnostic agents.Mt Sinai J Med. 2011 Sep-Oct;78(5):717-29. doi: 10.1002/msj.20290. Mt Sinai J Med. 2011. PMID: 21913201 Review.
-
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist.Ann Allergy Asthma Immunol. 2016 Aug;117(2):115-20. doi: 10.1016/j.anai.2016.05.013. Ann Allergy Asthma Immunol. 2016. PMID: 27499538 Review.
-
Adverse Reactions to Biologic Therapy.Immunol Allergy Clin North Am. 2017 May;37(2):397-412. doi: 10.1016/j.iac.2017.01.012. Epub 2017 Mar 2. Immunol Allergy Clin North Am. 2017. PMID: 28366484 Review.
-
Omalizumab and other biologics in drug desensitization.Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):333-337. doi: 10.1097/ACI.0000000000000648. Curr Opin Allergy Clin Immunol. 2020. PMID: 32398420 Review.
-
Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1564-1571. doi: 10.1016/j.jaip.2017.08.004. J Allergy Clin Immunol Pract. 2017. PMID: 29122155
Cited by
-
Engineering Versatile Nanomedicines for Ultrasonic Tumor Immunotherapy.Adv Sci (Weinh). 2024 Jan;11(3):e2305392. doi: 10.1002/advs.202305392. Epub 2023 Dec 2. Adv Sci (Weinh). 2024. PMID: 38041509 Free PMC article. Review.
-
Practical Management of New-Onset Urticaria and Angioedema Presenting in Primary Care, Urgent Care, and the Emergency Department.Perm J. 2021 Nov 22;25:21.058. doi: 10.7812/TPP/21.058. Perm J. 2021. PMID: 35348101 Free PMC article. Review.
-
Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors.Pharmaceutics. 2023 Aug 9;15(8):2110. doi: 10.3390/pharmaceutics15082110. Pharmaceutics. 2023. PMID: 37631324 Free PMC article. Review.
-
Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond.Int J Mol Sci. 2021 Jul 21;22(15):7785. doi: 10.3390/ijms22157785. Int J Mol Sci. 2021. PMID: 34360549 Free PMC article. Review.
-
Glutathione dynamics in subcellular compartments and implications for drug development.Curr Opin Chem Biol. 2024 Aug;81:102505. doi: 10.1016/j.cbpa.2024.102505. Epub 2024 Jul 24. Curr Opin Chem Biol. 2024. PMID: 39053236 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical